Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Wipro Limited — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.85 (market cap $5.08B), while Wipro Limited trades at $1.88 (market cap $17.75B). The key difference: Wipro Limited is far larger — about 3.5× Oruka Therapeutics Inc. Common Stock's market cap, and Wipro Limited pays a 4.82% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Wipro Limited for 41 Days on average.
| ORKA | WIT | |
|---|---|---|
Market Cap | $5.08B | $17.75B |
Volume | 685,276 | 5,443,754 |
Sector | Health | Technology |
52-Week High | $113.08 | $3.06 |
52-Week Low | $26.19 | $1.61 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $4.21B | $15.84B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wipro (WIT) trades at $1.80, up 5.88% with a bullish technical signal. The stock shows mixed fundamentals with declining revenue from $904.9B in 2023 to $890.9B in 2025, though net income improved to $131.4B. Recent AI initiatives have boosted productivity equivalent to 20,000 employees. Analyst consensus is cautious with only 19% buy ratings amid four consecutive quarterly earnings misses.
The outlook remains challenged by competitive pressures and client spending constraints, though strong cash flow generation and strategic partnerships provide stability. Key risks include execution on AI investments and margin pressure from wage increases. The stock offers value with a P/E of 13.7 but requires revenue growth acceleration to justify higher multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
